Stock Analysis
Abbott – Gotta Love It!
The only pharmaceutical company that we hold company wide is Abbott Labs (ABT). It has all the characteristics of the major pharmaceutical company: very strong balance sheet, great cash flows, nice fat profit margins and return on capital to die for.
Few accept slower growth gracefully
At some point even the most successful company will reach a size at which a supernormal growth rate is not possible. The law of large numbers is as inevitable as gravity, setting in slowly but surely.
Introduction to Minyanville
With this article Minyanville is proud to welcome Vitaliy Katsenelson to the 'Ville. Mr. Katsenelson holds a CFA and has worked in the asset management industry since 1995.
Bitter pill for pharmaceutical companies
In the good old days, pharmaceutical companies traded at a significant premium to the market, which was justified by predictable earnings growth, bulletproof balance sheets, Microsoft-monopoly-like profit margins and a return on investment that was the envy of corporate America. Those good old days are gone.
Future Looks Bright for Computer Associates
I'm satisfied with Computer Associates' performance in the latest quarter, plus, its organic growth numbers look good. I love companies with recurring revenues, Computer Associates has an attractive valuation, an improved corporate and financial profile - and, likely, a brighter future.
Ukraine Developments Are a Positive Sign
I would like to politely disagree with Jeff Matthews and politely agree with Geoff Johnson on the political situation in Ukraine. Though I am sometimes mistaken for an expert on Russia, I am not one.
Dollar General Fails to Show Me the Dollar
Last quarter I truly hoped that things could not get any worse for Dollar General (DG), but they did. I was a big believer in a Dollar General turnaround, but I think I was wrong.
Higher Rates Are a Clear and Present Danger to Economy
Consumers have carried the U.S. economy on their backs for a long time, but lately they are showing signs of fatigue. Consumers' response to higher food prices shows how frail they really are.
IMS Health: A Dusty Gem
IMS Health (IMS) is one such gem. On the surface, its financials look very rocky. Its sales and net income have not grown much over the years.
Becton Dickinson Finds ‘Sweet Spot’ Pharmas Have Missed
November 5, 2004 – TheStreet.com: Street Insight Predictability of revenue and earnings along with a likely dividend increase make BDX ...
Sara Lee Struggling to Pass on Higher Commodity Prices
October 27, 2004 – TheStreet.com: Street Insight Premium consumer brands no longer guarantee pricing power. Sara Lee (SLE) reported earnings ...
First Horizon on the Rise
October 26, 2004 – TheStreet.com: StreetInsight FHN is taking market share in the mortgage business from defunct small players. Management ...
Sirius Has Made a Deal with the Devil …
October 22, 2004 – TheStreet.com: Street Insight … and I don’t want to be around when payment is due. Paying ...
GM Bond Rating Downgraded by Fitch, Moody’s
October 14th 2004 – TheStreet.com: Street Insight If an investor was looking for a catalyst to short GM, this is ...
The Perfect Storm Is About To Hit Automotive Stocks
October 6, 2004 – TheStreet.com: Street Insight Rising interest rates, incentives, and declining profit margins are swirling around the automakers. ...
Searching for Truth in Stock Options, I Found Veritas
September 30, 2004 – TheStreet.com: Street Insight Veritas looked like a bargain, but when I adjust my cash-flow model for ...
Pharmaceutical Industry Went Legit, Distributors Went Down
September 28, 2004 – TheStreet.com: Street Insight Channel stuffing by pharmaceutical companies had handicapped the drug distribution industry. Drug distributors ...
Ending Channel Stuffing Will Pressure Drug Companies’ Multiples
September 23, 2004 – TheStreet.com: Street Insight The premium valuation multiple that the healthcare industry commanded in the past is ...
Merck – Positioning for a Sum-of-All-Fears Scenario
September 9, 2005 – TheStreet.com: Street Insight September 17, 2005 – Realmoney.com Recent clinical studies on Vioxx and Zocor do ...
Becton, Dickinson Finds ‘Sweet Spot’ Pharmas Have Missed
September 5, 2004 – TheStreet.com: Street Insight Predictability of revenue and earnings along with a likely dividend increase make BDX ...
A Contrarian View on Oil Prices
August 28, 2004 – TheStreet.com: Street Insight Consensus oil price forecasts are too aggressive, and are not sustainable in the ...
